Emergent BioSolutions, Inc.
Follow
400 Professional Drive
Suite 400
Gaithersburg, MD 20879
United States
Company Description
Emergent provides
contract development
and manufacturing
services for bulk
drug substances and
parenteral drug
products. Our
Fill/Finish services
include vials and
syringes for both
liquid and
lyophilized
products. We also
offer lyo cycle
development and
optimization. Our
global manufacturing
network currently
produces over 20
commercial products
and support a host
of clinical stage
programs.
|
|
 |
|
|
|
VITAL STATISTICS
|
|
|
Year Founded:1998
Number of Employees:1600
Key Personnel:
Robert Kramer, President & CEO; Sean Kirk, EVP, Manufacturing & Technical Operations; Syed T. Husain, SVP & Head of CDMO Business Unit |
|
|
|
WHO WE ARE
|
|
|
|
Emergent is a global life sciences company dedicated to one simple mission — to protect and enhance life. For over 20 years, Emergent has been dedicated to providing quality services and safety of our products for our customers in an effort to create a healthier world. We develop, manufacture, and deliver a portfolio of specialty products for civilian and military populations that address accidental, intentional, and naturally-emerging public health threats, such as medical countermeasures for biological and chemical threats as well as emerging infectious diseases. |
|
|
  |
|
|
|
MAJOR MARKETS
|
|
|
|
As a recognized Contract Development and Manufacturing Organization, Emergent can support fully integrated production of bulk drug substance and sterile injectable drug product, from Phase 1 development through commercial scale. Our highly experienced team incorporates research and full product/ process development to responsibly discover, develop, and/or commercialize innovative therapeutic products and technologies that protect and enhance life. Our state-of-the-art, single-use facility (located in Baltimore, MD) produces over 20 commercial products approved for distribution in over 50 countries, as well as clinical trial material for a wide range of Phase 1 – 3 programs. Since 1998, our global manufacturing network has supported over 200 drug product candidates, making Emergent a proven partner for pharmaceutical or biotechnology companies looking for value and reliability through outsourcing. |
|
|
|
SERVICES OFFERED
|
|
|
Drug Substance Development & Manufacturing:
• Process & Analytical Development
• Upstream & Downstream
• Clinical & Commercial Scale
• Single-Use Platform (up to 4000L)
• Mammalian Cell Culture
• Viral
• Bacterial Fermentation |
Drug Product Development & Manufacturing:
• Small Molecules & Biologics
• Viral & Non-Viral Fill/Finish
• Parenteral Formulation Development
• Lyophilization Cycle Development
• Clinical & Commercial Scale
• Liquid & Lyophilized Products
• Vials & Prefilled Syringes
• Microbiology
• ICH Stability |
Contract Service Categories
Contract Services Directory
| Accelerated Stability Studies |
| Analytical Laboratory Services |
| Analytical Validation Studies |
| Assay Development |
| Biosimilars |
| Cell Line Construction & Development |
| Clinical Trials, Phase I |
| Clinical Trials, Phase II |
| CMC (Chemistry, Manfacturing & Controls) |
| Contract Development and Manufacturing Organization (CDMO) |
| Contract Manufacturing |
| Distribution, Commercial |
| Downstream Processing |
| Fermentation |
| Filling, Syringe |
| Filling, Vial |
| Lot Release Testing |
| Lyophilization |
| Manufacturing, Aseptic Fill/Finish |
| Manufacturing, Clinical Trials Supply |
| Manufacturing, Dose Form, Sterile |
| Manufacturing, Injectables |
| Manufacturing, Liquids |
| Manufacturing, Lyophilized Products |
| Manufacturing, Microbial-based Therapeutic Proteins |
| Manufacturing, Oligonucleotides |
| Manufacturing, Parenterals, Small Volume |
| Manufacturing, Peptides |
| Manufacturing, Proteins |
| Manufacturing, Syringes, Pre-filled |
| Manufacturing, Vaccines |
| Manufacturing, Veterinary |
| Packaging, Injectables |
| Parenterals, Syringe Filling |
| Parenterals, Vial Filling |
| Process Development/Scale-Up Services |
| Process Validation Studies |
| Purification |
| QA/QC |
| Stability Studies |
| Stability, ICH |
| Sterile Filling |
| Sterility Testing |
| Syringe Filling |
| Technology Transfer |
Content From Emergent BioSolutions, Inc.
-
Download our CMO Services Brochure
-
INTEGRATED LYO CYCLE DEVELOPMENT AND MANUFACTURING SERVICES
-
At Emergent BioSolutions our mission is to protect and enhance life.
-
GAITHERSBURG, Md., Feb. 01, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the initiation of a Phase 1b multiple ascending dose study to evaluate the safety and tolerability of UV-4B, the company…
-
GAITHERSBURG, Md., Jan. 27, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that the Paul-Ehrlich-Institut (PEI), the regulatory agency under the German Federal Ministry of Health, has approv…
-
GAITHERSBURG, Md., Jan. 09, 2017 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced preliminary unaudited 2016 financial results and guidance for 2017.
Daniel J. Abdun-Nabi, president and chief execut…
-
GAITHERSBURG, Md., Dec. 29, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) announced today that a member of the company’s senior management team will participate in the following investor conferences durin…
-
GAITHERSBURG, Md., Dec. 12, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that Health Canada has approved the company’s New Drug Submission (NDS) for its botulism antitoxin, BAT&…
-
Company signs follow-on contract with CDC valued at up to $911 million to supply to the SNS approximately 29.4 million doses of BioThrax through September 2021
BARDA issues noti…
-
GAITHERSBURG, Md., Nov. 08, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Kathryn C. Zoon, Ph.D. to the company’s Board of Directors. Dr. Zoon is currently a Scientist E…
-
GAITHERSBURG, Md., Nov. 07, 2016 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) reported financial results for the quarter and nine months ended September 30, 2016.
FINANCIAL HIGHLIGHTS
The following fin…
-
Emergent BioSolutions Inc. (NYSE:EBS) will host a conference call on Thursday, August 6, 2015 at 8:00 am (Eastern Time).
-
Company Receives Its First Ebola-Related BARDA Task Order
-
Emergent Leverages Manufacturing and Plasma Fractionation Expertise to Create Opportunities for Future Revenue Growth
-
OXFORD, U.K., LONDON and GAITHERSBURG, Md., May 13, 2015 (GLOBE NEWSWIRE) -- A new phase 1 study has begun at the University of Oxford that will investigate the use of a modified vaccinia Ankara (MVA) Ebola Zaire vaccine candidate (MVA EBOZ) as a pri…
